Lilly osteoporosis agent in pulmonary form being developed with Inhale.
Executive Summary
LILLY DEVELOPING INHALED OSTEOPOROSIS AGENT WITH INHALE THERAPEUTIC SYSTEMS through a collaborative agreement worth up to $20 mil. Palo Alto, Calif.-based Inhale will apply its deep-lung delivery system for macromolecules to the Lilly osteoporosis drug, presumably raloxifene (Evista).